Rus Eng
Main / Company's news / Belarus is going to produce insulins using GEROPHARM technology

Belarus is going to produce insulins using GEROPHARM technology

On July 17, there was an official signing ceremony for the partnership agreement between GEROPHARM and NatiVita (Belarus) that stipulates a transfer of the Russian insulin production technology to the Belarussian party.

17 July 2019

On July 17, there was an official signing ceremony for the partnership agreement between GEROPHARM and NatiVita (Belarus) that stipulates a transfer of the Russian insulin production technology to the Belarussian party.

This partnership between the companies is a strategy and facilitates strengthening bilateral relationship between the Russian Federation and the Republic of Belarus. Implementation of the project will make it possible to adjust highly technological production of insulins in Belarus within a short-term period of time and provide the citizens with modern, effective and affordable drugs.

According to the Republican Register “Diabetes Mellitus” there are more than 320,000 people with this diagnosis in the country with 67,000 of them needing everyday insulin injections.

GEROPHARM carries out a technological transfer to NatiVita production site with a perspective to localize production of finished dosage form. NatiVita in its turn will be fully responsible for distribution of the products.

Within the project Belarus will launch 5 insulins produced using GEROPHARM technology: human genetically engineered insulins of short-term and middle-term effect – Rinsulin® R and Rinsulin® NPH, and the analogues – Lispro (RinLis®) and Glargine (RinGlar®). Currently, possible localization of insulin Aspart that undergoes the third stage of clinical studies in Russia at the moment is being considered

According to the internal estimate of NatiVita, a total market of insulins in Belarus amounts to about 12.6 million dollars. GEROPHARM is going to take 30 % of the market within the next few years. The company’s insulins may appear at the market as soon as in 2020. The total volume of GEROPHARM deliveries can reach 7 million doses of insulin per year within the next 3 years.

It should be noted that at the moment Belarus is only selling human genetically engineered insulins in cartridges and vials, and the analogues are less common. The market of insulins is associated with high level of competition – both international and local companies are presented there.

Pyotr Rodionov, GEROPHARM CEO: “Belarus is the market we know very well. It covers over 8 % of GEROPHARM export sales. The original products of the company – Cortexin® and Retinalamin® – have been presented here since 2007. The agreement concluded today is one more step towards development of business relationship with Belarus. We already have a successful experience of technological transfer of insulin production to Kazakhstan. We are glad that our expertise and technologies in the area of insulin production are noticed and demanded in friendly states. A reliable partner with strong positions at the market and a highly developed production infrastructure in Belarus makes it possible to count on successful implementation of the project in no time. In general, insulin export development is a strategic task for the company. The number of our international projects is growing day by day and we expect the share of export to increase up to 30 % of the total sales volume of the company within the next few years.”

***

GEROPHARM is a Russian biotechnological company, a leader in insulin development and production. The Company has been occupying the first position by sales volume among the manufacturers of human genetically engineered insulins (HGEI) since the end of 2016. Today, the company provides about 30 % of the Russian Federation demand for HGEI.

All stages of insulin production, including the molecule biosynthesis, are carried out at the company’s own production facilities in the Russian Federation. In 2018, the company held an opening ceremony for a new factory in Pushkin (St. Petersburg) with participation of the Russian President, Vladimir Putin.

The line manufacturing capacity at the site in Pushkin is over 1,000 kg of substance per year, which, after reaching the design capacity, will allow to fully satisfy the needs of Russian residents in insulin (about 800 kg per year) and will expand the company’s export capabilities.

The project was implemented with participation of the state development institutions – the Russian Direct Investment Fund, the Fund of Industrial Development.

The company’s portfolio in the field of endocrinology includes two human genetically engineered insulins (HGEI) – Rinsulin® R and Rinsulin® NPH, as well as an analog of insulin with an ultra short and medium duration of action RinLis® and RinLis®Mix 25. Another 7 products are being developed (insulin analogues and HGEI), 2 of them are expected to be registered soon.

NatiVita is an international scientific and production pharmaceutical company developing and releasing innovative medicinal products to treat cancerous, autoimmune and other severe disease. The company is included in top 3 companies at the hospital Belarussian market and occupies strong leading position in cancerous segment.

NatiVita has a scientific and research complex that includes microbiological and chemical laboratory, a workshop manufacturing medicinal products, the departments of pharmacy developments and registration of medicinal products under the department of production and development of technologies as well as medical and scientific departments and others. The company’s production site is situated the town of Beshankovichy (Vitebsk Province, Belarus).

In its work the company is focused on modern achievements in medicine and biotechnologies, it is looking for the most safe and effective drugs to fight severe diseases in order to make them affordable for most of the patients. The company portfolio contains 21 medicinal products including biological/biotechnological drugs, bio analogues and generic medicinal products

You are a health care professional?

Go up